229 related articles for article (PubMed ID: 19110454)
1. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
[TBL] [Abstract][Full Text] [Related]
2. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.
Pectasides D; Pectasides E; Papaxoinis G; Skondra M; Gerostathou M; Karageorgopoulou S; Kamposioras C; Tountas N; Koumarianou A; Psyrri A; Macheras A; Economopoulos T
J Androl; 2009; 30(3):280-6. PubMed ID: 19136393
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of TIP (paclitaxel, ifosfamide, cisplatin) into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy: a report of three cases.
Ishioka J; Kageyama Y; Ichiyanagi N; Fukuda H; Higashi Y
Int J Urol; 2007 May; 14(5):455-7. PubMed ID: 17511735
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
9. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Hlavatá Z; Mego M; Recková M; Koza I
Neoplasma; 2005; 52(6):497-501. PubMed ID: 16284696
[TBL] [Abstract][Full Text] [Related]
11. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
Rick O; Siegert W; Beyer J
Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
14. Germ-cell tumors.
Kondagunta V; Galsky MD; Sonpavde G
N Engl J Med; 2007 Oct; 357(17):1773; author reply 1773-4. PubMed ID: 17969229
[No Abstract] [Full Text] [Related]
15. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
Banna GL; De Giorgi U; Ferrari B; Castagna L; Alloisio M; Marangolo M; Rosti G; Santoro A
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1085-91. PubMed ID: 17084372
[TBL] [Abstract][Full Text] [Related]
16. Treatment results in children and adolescents with loco-regional recurrences of abdominal germ cell tumors (GCTs): a pilot-study with PEI chemotherapy and regional deep hyperthermia (RHT) in comparison to a matched cohort.
Wessalowski R; Blohm M; Calaminus G; Engert J; Harms D; Krause I; Kruck H; Grüttner HP; Pape H; Göbel U
Klin Padiatr; 1997; 209(4):250-6. PubMed ID: 9293458
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.
Feldman DR; Hu J; Dorff TB; Lim K; Patil S; Woo KM; Carousso M; Hughes A; Sheinfeld J; Bains M; Daneshmand S; Ketchens C; Bajorin DF; Bosl GJ; Quinn DI; Motzer RJ
J Clin Oncol; 2016 Jul; 34(21):2478-83. PubMed ID: 27185842
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
Nonomura N; Oka D; Nishimura K; Nakayama M; Inoue H; Mizutani Y; Miki T; Okuyama A
Int J Urol; 2007 Jun; 14(6):527-31. PubMed ID: 17593098
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
Kondagunta GV; Bacik J; Sheinfeld J; Bajorin D; Bains M; Reich L; Deluca J; Budnick A; Ishill N; Mazumdar M; Bosl GJ; Motzer RJ
J Clin Oncol; 2007 Jan; 25(1):85-90. PubMed ID: 17194908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
